Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- JCR, Teijin to Codevelop Regenerative Medicine Product, Plan to Begin Clinical Studies in 2018
July 19, 2017
- Sunovion to Divest Asthma and Allergy Products to Focus on COPD
July 18, 2017
- Bayer Yakuhin to Ban Any Type of Medical Affairs Work by Sales Organization
July 18, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
- Ambicion, RIKEN Pair Up for Joint Research to Develop Novel Antiallergics
July 14, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Rejected: Nippon Chemiphar/Nagase
July 13, 2017
- Daiichi Sankyo Links Up with Max Planck Innovation, LDC on Cancer Research
July 13, 2017
- Vemlidy Counterfeit with Japanese Label Found in China
July 13, 2017
- Biogen, Univ. of Tokyo Establish Research Program on “Pharmacotherapeutics for Neuropsychiatric Disorders”
July 13, 2017
- Astellas Pursuing Corrective Measures after ABPI Suspension Extension: CEO
July 12, 2017
- Astellas Eager to Take in External Resources; Key Xtandi Data Out Later This Year
July 12, 2017
- Boehringer Ingelheim, NCC Forge Comprehensive Partnership
July 12, 2017
- Daiichi Sankyo’s Oncolytic Virus Gets Orphan Status
July 12, 2017
- Ethical Drug Sales Tick Up 1.7% in May: Crecon
July 12, 2017
- Mundipharma Inks Partnership with J1 Soccer Team, Isodine Logo Put on Uniform
July 11, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
- Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…